The Breast International Group, the European Organization for Research and Treatment of Cancer and the Alliance Foundation Trials groups are collaborating with Sanofi to initiate a pivotal trial of an oral selective estrogen receptor degrader (SERD) in the adjuvant setting.
The FDA Oncologic Drugs Advisory Committee July 25 voted unanimously to set more rigorous standards for new trials for approval of perioperative indications of cancer drugs.
